Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Three-dose vaccination elicits neutralising antibodies against omicron
Mary Wu, Emma Wall, Edward J Carr, et al.
The Lancet (2022) Vol. 399, Iss. 10326, pp. 715-717
Open Access | Times Cited: 91

Showing 1-25 of 91 citing articles:

SARS-CoV-2 Omicron variant: recent progress and future perspectives
Yao Fan, Xiang Li, Lei Zhang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 471
Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes
Sarah A. Buchan, Hannah Chung, Kevin A. Brown, et al.
JAMA Network Open (2022) Vol. 5, Iss. 9, pp. e2232760-e2232760
Open Access | Times Cited: 277
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
Annika Fendler, Elisabeth G.E. de Vries, Corine H. GeurtsvanKessel, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 6, pp. 385-401
Open Access | Times Cited: 178
Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins
Zijun Wang, Frauke Muecksch, Alice Cho, et al.
Immunity (2022) Vol. 55, Iss. 6, pp. 998-1012.e8
Open Access | Times Cited: 128
Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes
Sarah A. Buchan, Hannah Chung, Kevin A. Brown, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 120
Nanotechnology-based strategies against SARS-CoV-2 variants
Xiangang Huang, Edo Kon, Xuexiang Han, et al.
Nature Nanotechnology (2022) Vol. 17, Iss. 10, pp. 1027-1037
Open Access | Times Cited: 102
SARS-CoV-2 S2–targeted vaccination elicits broadly neutralizing antibodies
Kevin W. Ng, Nikhil Faulkner, Katja Finsterbusch, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 655
Open Access | Times Cited: 84
Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer
Annika Fendler, Scott T.C. Shepherd, Lewis Au, et al.
The Lancet (2022) Vol. 399, Iss. 10328, pp. 905-907
Open Access | Times Cited: 81
Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study
Susana Monge, Ayelén Rojas‐Benedicto, Carmen Olmedo, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 9, pp. 1313-1320
Open Access | Times Cited: 72
COVID-19 vaccine booster dose needed to achieve Omicron-specific neutralisation in nursing home residents
David H. Canaday, Oladayo A. Oyebanji, Elizabeth M. White, et al.
EBioMedicine (2022) Vol. 80, pp. 104066-104066
Open Access | Times Cited: 46
Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose
Laurent Rénia, Yun Shan Goh, Angéline Rouers, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 44
Vaccination and immunotherapies in neuroimmunological diseases
Alexander Winkelmann, Micha Loebermann, Michael Barnett, et al.
Nature Reviews Neurology (2022) Vol. 18, Iss. 5, pp. 289-306
Open Access | Times Cited: 42
Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: a population-based study
María‐Eugenia Zaballa, Javier Perez‐Saez, Carlos de Mestral, et al.
The Lancet Regional Health - Europe (2022) Vol. 24, pp. 100547-100547
Open Access | Times Cited: 41
WHO's Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed
Mary Wu, Edward J Carr, Ruth Harvey, et al.
The Lancet (2022) Vol. 400, Iss. 10369, pp. 2193-2196
Open Access | Times Cited: 39
Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection
Edward J Carr, Mary Wu, Joshua Gahir, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 7, pp. 781-784
Open Access | Times Cited: 28
SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines
Raju Sunagar, Amit Kumar Singh, Sudeep Kumar
Vaccines (2023) Vol. 11, Iss. 4, pp. 849-849
Open Access | Times Cited: 23
Significance of Conserved Regions in Coronavirus Spike Protein for Developing a Novel Vaccine against SARS-CoV-2 Infection
Titus Abiola Olukitibi, Zhujun Ao, Bryce M. Warner, et al.
Vaccines (2023) Vol. 11, Iss. 3, pp. 545-545
Open Access | Times Cited: 21
Combined analyses of within-host SARS-CoV-2 viral kinetics and information on past exposures to the virus in a human cohort identifies intrinsic differences of Omicron and Delta variants
Timothy Russell, Hermaleigh Townsley, Sam Abbott, et al.
PLoS Biology (2024) Vol. 22, Iss. 1, pp. e3002463-e3002463
Open Access | Times Cited: 8
COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.4/5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination history
Hermaleigh Townsley, Joshua Gahir, Timothy Russell, et al.
PLoS ONE (2024) Vol. 19, Iss. 3, pp. e0294897-e0294897
Open Access | Times Cited: 7
BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19
Georg M. N. Behrens, Joana Barros‐Martins, Anne Cossmann, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 35
Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2
Feyza Gül Özbay Kurt, Alisa Lepper, Catharina Gerhards, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 33
Strong peak immunogenicity but rapid antibody waning following third vaccine dose in older residents of care homes
Gokhan Tut, Tara Lancaster, Maria Krutikov, et al.
Nature Aging (2023) Vol. 3, Iss. 1, pp. 93-104
Open Access | Times Cited: 17
Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant
G Pastore, Jacopo Polvere, Fabio Fiorino, et al.
Expert Review of Vaccines (2024) Vol. 23, Iss. 1, pp. 432-444
Open Access | Times Cited: 5
Accurate evaluation of live-virus microneutralisation for SARS-CoV-2 variant JN.1 in the assessment of vaccination and therapeutics
Giulia Dowgier, Agnieszka Hobbs, David Greenwood, et al.
Vaccine (2025) Vol. 54, pp. 126960-126960
Closed Access
Electrochemical Immunosensors Based on Zinc Oxide Nanorods for Detection of Antibodies Against SARS-CoV-2 Spike Protein in Convalescent and Vaccinated Individuals
Freddy A. Nunez, Ana Cristina Honorato de Castro, Vivian L. de Oliveira, et al.
ACS Biomaterials Science & Engineering (2022) Vol. 9, Iss. 1, pp. 458-473
Closed Access | Times Cited: 26
Page 1 - Next Page

Scroll to top